FLINT, Mich.--(EON: Enhanced Online News)--Initial acceptance test results of ProTom International, Inc.'s (“ProTom”) Radiance 330® Proton Therapy System (“Radiance 330”) are exceeding the expectations of medical physicists charged with clinical commissioning at the McLaren Proton Therapy Center (“MPTC”) in Flint, Michigan.
“The raw data is extremely clean and smooth.”
Speaking of the depth-dose data acquired from the scanning proton beam system during acceptance testing, McLaren's principal consulting physicist Alfred R. Smith, Ph.D. stated, “The raw data is extremely clean and smooth.” Depth-dose profiles characterize the key quality of protons – the Bragg peak – a physical property of charged-particle beams causing the vast majority of proton energy to be delivered over a short and precisely-defined range, confining the high dose to the target volume and sparing normal tissues in close proximity.
The Radiance 330® employs the Proton Beam Scanning (PBS) treatment delivery technique, and the McLaren team tested key characteristics of the scanned beam delivered to instrumentation in water phantoms. “We have been impressed by the stability of the system during our testing,” said Sung Park, Ph.D., Chief Physicist for the MPTC. “The spot size and spot profiles are well-described by a Gaussian distribution and demonstrate excellent radial symmetry. This bodes well for the dosimetry we can expect from ProTom's system.”
Dr. Park continued, “We observed very impressive beam performance during ProTom’s technical commissioning, and these results are now being independently measured and reproduced by our clinical physics team. We have collected all the data necessary to validate our treatment planning system for Radiance 330. Beam modeling is underway; next, we’ll deliver some sample plans to phantom for comparison. We look forward to clinically commissioning our first patient treatment room.”
About ProTom International, Inc.
ProTom is a medical device company committed to offering the most advanced and affordable generation of proton therapy systems so that patients in need of this cutting-edge treatment may have this option close to home, close to their physicians. ProTom continues to accelerate innovation so physicians and the patients they care for can have the very best weapons in the fight against cancer. To find out more about the future of proton therapy, visit us at www.protominternational.com.
About McLaren Health Care
McLaren Health Care Corporation, headquartered in Flint, MI, is a fully integrated health network, committed to quality, evidence-based patient care and cost efficiency. The McLaren system includes 11 hospitals, ambulatory surgery centers, imaging centers, the state’s only proton therapy center, an employed primary care physician network, commercial and Medicaid HMOs covering over 250,000 lives, home health care and hospice, durable medical equipment, retail pharmacy services, and a wholly-owned medical malpractice insurance company. McLaren operates the state’s largest network of cancer centers and providers anchored by Karmanos Cancer Institute - one of only two NCI-designated cancer centers in the state. McLaren has 19,500 employees and more than 20,000 network physicians. The operations and services of MHC are housed in over 300 facilities serving a 53-county market with a population in excess of 6.5 million lives. Learn more at www.mclaren.org.
The Radiance 330® Proton Therapy System has not been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution in the U.S. at this time.